Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (EG_PG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02263495
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : July 14, 2020
Sponsor:
Collaborators:
Eisai Inc.
Dong-A ST Co., Ltd.
Samyang Biopharmaceuticals Corporation
Information provided by (Responsible Party):
Kyung Hae Jung, Asan Medical Center

Tracking Information
First Submitted Date  ICMJE October 6, 2014
First Posted Date  ICMJE October 13, 2014
Last Update Posted Date July 14, 2020
Actual Study Start Date  ICMJE December 19, 2014
Actual Primary Completion Date May 11, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 10, 2014)
Progression free survival [ Time Frame: 48months ]
To demonstrate that EG is not inferior to PG group in terms of PFS in patients with metastatic or recurrent breast cancer as first-line treatment.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 1, 2018)
  • overall survival [ Time Frame: 48months ]
    Survival will be measured as the time from randomization to the date of death.
  • neuropathic scale [ Time Frame: expected at 9week , expected at 24week ]
    FACT for Taxane QOL assessment
  • toxicity of study drugs [ Time Frame: from first administration until 28 days after the last dose administration ]
    Using CTCAE Version 4.0
  • duration of response [ Time Frame: 48months ]
    using RECIEST version 1.1
  • objective response rate [ Time Frame: 48months ]
    using RECIEST version 1.1
  • clinical benefit rate [ Time Frame: 48months ]
    using RECIEST version 1.1
Original Secondary Outcome Measures  ICMJE
 (submitted: October 10, 2014)
  • overall survival [ Time Frame: 48months ]
    Survival will be measured as the time from randomization to the date of death.
  • neuropathic scale [ Time Frame: expected at 9week , expected at 24week ]
    FACT for Taxane QOL assessment
  • toxicity [ Time Frame: from first administration until 28 days after the last dose administration ]
    Using CTCAE Version 4.0
  • duration of response [ Time Frame: 48months ]
    using RECIEST version 1.1
  • objective response rate [ Time Frame: 48months ]
    using RECIEST version 1.1
  • clinical benefit rate [ Time Frame: 48months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Official Title  ICMJE A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy
Brief Summary

Metastatic breast cancer (MBC) is an incurable disease and is needed to improve effective chemotherapy. Paclitaxel plus Gemcitabine (PG) combination chemotherapy is one of the preferred chemotherapeutic regimens for patients with MBC, and was found to be proper as a maintenance chemotherapy regimen with survival benefit and feasible toxicity profile as shown in a large phase III KCSG (Korean Cancer Study Group) study (Park Y et al. J Clin Oncol 31(14):1732, 2013).

Eribulin mesylate is a microtubule-targeting agent that showed improved overall survival benefit as monotherapy for MBC patients as a new chemotherapeutic agent after failure of anthracycline and taxane in EMBRACE study (Cortes J et. al. Lancet 377:914-923, 2011). Eribulin was also reported its promising efficacy in another randomized phase III study that demonstrated eribulin as efficacious as capecitabine (Kaufman P et. al. Abstr# S6-6, SABCS 2012). Both study results showed potential clinical benefit in patients with triple negative MBC (TNBC). Thus, eribulin combined with gemcitabine may be a new potential regimen for early line therapy in patients with metastatic breast cancer.

Furthermore, eribulin may have rational benefit compared with paclitaxel in terms of neurotoxicity. Although there is no direct evidence that eribulin has better neurotoxicity profile than taxane, eribulin tended to show less neurotoxicity compared with ixabepilone in a phase II trial (Vahdat, L et al. 2011 SABCS). Eribulin has no worsen toxicity as compared to paclitaxel. Therefore, EG may have less neurotoxicity comparing to PG.

In phase I trial, eribulin in combination with gemcitabine was feasible in patients with advanced solid tumor treated with chemotherapy (< 3 lines) (Goel R, et al, 2009 ASCO).

Based on this rationale, the investigators are to conduct randomized phase II study comparing EG chemotherapy with PG chemotherapy for patients with HER-2 negative MBC as first-line chemotherapy.

A total of 118 patients will be recruited. Patients will be randomized to a treatment arm by permutated method. The randomization ratio is 1:1. This study is multi-center, randomized, open label study.

Detailed Description

A total of enrolled 118 patients in EG and PG groups, will be provided chemotherapy regimen:

Paclitaxel/Gemcitabine (PG) : every 3 weeks D1 Paclitaxel 175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration D1, D8 Gemcitabine 1,250 mg/m2 + NormalSaline 100ml MIV over 30mins

  • Pre & Post medication (which can be changed according to institutions' policy) D1 Corticosteroid 100 mg i.v. 30 min. before Paclitaxel Pheniramine 1A + D5W 50mL MIV 30mins before Paclitaxel Ranitidine 50mg IV + D5W 50mL MIV 30mins before Paclitaxel HT3 antagonist 1A + D5W 50 mL MIV 30mins before Paclitaxel

Eribulin/Gemcitabine (EG): every 3weeks D1, D8 Eribulin 1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NormalSaline 100ml in max.) D1, D8 Gemcitabine 1000 mg/m2 + NormalSaline100ml MIV over 30mins

<schedule of Assessment adn procedures (±3 days window period ) >

  1. screening /baseline

    • obtaining Informed consent form
    • collecting information
    • demographic data
    • breast cancer treatment history/ medical history
    • general physical examination/ vital sign & Performance status
    • Test: CBC/blood chemistry/ Tumor response(CT or MRI)/
    • collecting QOL questionnaire using FACT-Taxane
  2. cycle 1 ~ prior to EOT

    • general physical examination/ vital sign & Performance status
    • Test: CBC/blood chemistry/ Tumor response(CT or MRI)
    • collecting QOL questionnaire using FACT-Taxane
    • administration PG or EG
  3. EOT(end of treatment)

    • general physical examination/ vital sign & Performance status
    • Test: CBC/blood chemistry/ Tumor response(CT or MRI)
    • collecting QOL questionnaire using FACT-Taxane
  4. survival follow up(every 12weeks)

    • survival
    • anti neoplastic therapy after end of treatment
    • The tumor response will be performed every 12 (±2) weeks until disease progression

<WITHDRAWAL OF SUBJECTS>

Subjects may be withdrawn from the study (i.e. from any further study medication or study procedure) for the following reasons:

  • At their own request
  • If, in the investigator's opinion, continuation in the study would be detrimental to the subject's well-being
  • In case of disease progression
  • In case of unacceptable toxicity
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Paclitaxel
    175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
    Other Name: Genexol,
  • Drug: Eribulin
    1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
    Other Name: Halaven,
  • Drug: Gemcitabine
    PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
    Other Name: Gemcit
Study Arms  ICMJE
  • Active Comparator: Paclitaxel & Gemcitabine(PG)
    Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1& Day8 every 3weeks
    Interventions:
    • Drug: Paclitaxel
    • Drug: Gemcitabine
  • Experimental: Eribulin & Gemcitabine(EG)
    Eribulin 1.0 mg/m2, 2-5min iv ,Day1& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1& Day8 every 3weeks
    Interventions:
    • Drug: Eribulin
    • Drug: Gemcitabine
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 22, 2016)
118
Original Estimated Enrollment  ICMJE
 (submitted: October 10, 2014)
112
Actual Study Completion Date  ICMJE June 17, 2019
Actual Primary Completion Date May 11, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically confirmed metastatic, or recurrent breast cancer
  2. HER2-negative breast cancer
  3. age > 18 years
  4. ECOG performance status 0 - 2
  5. Pre- or postmenopausal breast cancer patients with measurable or non-measurable lesions, who are candidates for chemotherapy
  6. Life expectancy ≥ 3 months
  7. No prior history of chemotherapy for metastatic, recurrent breast cancer
  8. Patients may have received prior neoadjuvant or adjuvant taxane regimen as long as it has been 12 months since completion of regimen.
  9. Patients either may or may not have a prior anthracycline containing regimen.
  10. Prior hormonal therapy as a treatment of metastatic disease is allowed. But antitumoral hormonal therapy must be terminated prior to enrollment(up to the date of randomization)
  11. Prior radiation therapy allowed as long as < 25% of the bone marrow has been treated, and the patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed 2 weeks before study entry.
  12. Bisphosphonates for the treatment of bone metastases should not be initiated following the first dose of randomized therapy. It must be initiated prior to day of treatment (cycle 1, day 1). Patients may continue on bisphosphonates who already established on bisphosphonate therapy for bone metastases
  13. Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl)
  14. Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 50 ml/min)
  15. Adequate liver function (≤ serum bilirubin 1.5 mg/dl, ≤ AST & ALTX3 upper normal limit or AST and ALT ≤ 5.0XULN if judged by the investigator to be related to liver metastases)
  16. Written informed consent

Exclusion Criteria:

  1. Serious uncontrolled intercurrent infections
  2. Serious intercurrent medical or psychiatric illness, including active cardiac disease
  3. Pregnancy or breast feeding
  4. Second primary malignancy(except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence)
  5. Documented parenchymal or leptomeningeal brain metastasis
  6. Peripheral neuropathy ≥ grade 2
  7. Prior treatment with gemcitabine will not be allowed.
  8. HER-2 overexpressing breast cancer and concomitant trastuzumab treatment is not allowed
  9. Women of childbearing potential, unwilling to use a medically acceptable method of contraception during the trial
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02263495
Other Study ID Numbers  ICMJE 2014-0857
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Kyung Hae Jung, Asan Medical Center
Study Sponsor  ICMJE Asan Medical Center
Collaborators  ICMJE
  • Eisai Inc.
  • Dong-A ST Co., Ltd.
  • Samyang Biopharmaceuticals Corporation
Investigators  ICMJE
Principal Investigator: Kyung Hae Jung, Dr Asan Medical Center
PRS Account Asan Medical Center
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP